• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 4, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

World Hepatitis Day 2024: Madrid study shows decrease in active hepatitis C infection among risk groups, indicating effectiveness of public health measures

by
July 25, 2024
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A study conducted through a mobile screening unit in Madrid, Spain from 2017 to 2023 and published in Eurosurveillance found that active hepatitis C virus (HCV) infection decreased from 23% to 6% in that period among people who use drugs (PWUD) that visited the unit. The study found that the use of intravenous drugs was the most significant risk factor for infection among PWUD. It confirmed that HCV screening and treatment programmes targeting this at-risk population are effective and can help achieve the World Health Organization goal of HCV elimination as public health threat by 2030.

Prevalence of active HCV infection in the PWUD population, stratified by injecting drug use, Madrid, Spain, 1 June 2017–3 April 2023 (n = 2,414 PCR tests)

Credit: Eurosurveillance

A study conducted through a mobile screening unit in Madrid, Spain from 2017 to 2023 and published in Eurosurveillance found that active hepatitis C virus (HCV) infection decreased from 23% to 6% in that period among people who use drugs (PWUD) that visited the unit. The study found that the use of intravenous drugs was the most significant risk factor for infection among PWUD. It confirmed that HCV screening and treatment programmes targeting this at-risk population are effective and can help achieve the World Health Organization goal of HCV elimination as public health threat by 2030.

Study participants and methods

Participants were recruited in ‘hotspots’ in Madrid where high-risk individuals gathered for dealing and drug consumption. The study included individuals over 18 and with active drug use in the year before being screened.

A mobile screening unit approached these ‘hotspots’’. A nurse collected blood samples from participants for HCV testing, and investigators gathered data on demographic, epidemiology, substance use and sexual risk behaviour.

Results and public health implications

2 349 participants of the initial cohort of 5 270 were actively using drugs. Of these, 2 264 (43%) underwent an HCV antibody test, with 195 (8.6%) participating more than once. Among the group who were tested, 685 (13%) tested positive for anti-HCV antibodies. Of those, 605 participants agreed to undergo HCV-RNA testing, with an active HCV infection detected in 314 (51.9%) individuals.

Participants who reported using drugs and with an active HCV infection were significantly older and were more likely to be of European (Western Europe and Eastern Europe) origin, homeless, consuming cocaine and heroin, injecting drugs, and undergoing opioid substitution treatment than participants who used drugs without an active HCV infection. Significantly, the use of a mobile screening unit led almost 70% of participants who tested positive to start treatment.

The study observed a strong decrease in active HCV infection across the entire population from 23.4% in 2017 to 6% in 2023. However, the prevalence remains 30 and 70 times higher among people who use drugs and people who inject drugs, respectively, than in the general population.

The decrease could be attributed to measures that have helped users of intravenous drugs overcome barriers to testing and treatment, such as better access to testing and care through decentralised approaches, simplified one-step diagnosis, and fewer treatment restrictions. Public health campaigns have also helped raise awareness of the risks related to intravenous drug use.

Additional outputs on hepatitis

Ahead of World Hepatitis Day, Eurosurveillance has also published a study conducted in Australia demonstrating the feasibility and effectiveness of using surveillance systems to improve access to treatment and care of hepatitis C. Additionally, it has published research on the prevalence of chronic hepatitis C infections in Estonia and Romania, with levels shown to be low in both countries, as well as an accompanying editorial highlighting steps needed to achieve the goal of eliminating hepatitis C as public health threat by 2030.



Journal

Eurosurveillance

DOI

10.2807/1560-7917.ES.2024.29.29.2300712

Method of Research

Observational study

Subject of Research

People

Article Title

Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study

Article Publication Date

18-Jul-2024

COI Statement

None declared.

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Psychedelics and Non-Hallucinogenic Analogs Activate the Same Receptor—But Only to a Certain Extent

August 4, 2025
Cellular Senescence: Key Aging and Disease Mechanisms

Cellular Senescence: Key Aging and Disease Mechanisms

August 4, 2025

Intersectin-Endophilin Condensates Prime Synaptic Vesicle Release

August 4, 2025

Timed Progenitor Competence Guides Mouse GABA Neuron Maturation

August 4, 2025

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    54 shares
    Share 22 Tweet 14
  • Predicting Colorectal Cancer Using Lifestyle Factors

    44 shares
    Share 18 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Debating Microplastics in Blood: New Analysis Sparks Discussion

Psychedelics and Non-Hallucinogenic Analogs Activate the Same Receptor—But Only to a Certain Extent

Urinary Tract Cancer Trends in Golestan Revealed

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.